Robert E Smith, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3080 Ackerman Blvd, Ste 100, Kettering, OH 45429 Phone: 937-396-1605 Fax: 937-396-1607 |
Mr. George Gateley Burton, MD Internal Medicine - Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 5250 Far Hills Ave, Suite #150, Kettering, OH 45429 Phone: 937-434-4611 Fax: 937-434-9107 |
Dr. Robert A Cain, D.O Internal Medicine - Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 5250 Far Hills Ave, Suite 210, Kettering, OH 45429 Phone: 937-433-9053 Fax: 937-433-9054 |
Mr. Raymond G. Russell, M.D. Internal Medicine - Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 5250 Far Hills Ave, Suite 150, Kettering, OH 45429 Phone: 937-434-4611 Fax: 937-434-9107 |
Felipe A Rubio, MD Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3080 Ackerman Blvd, Suite 100, Kettering, OH 45429 Phone: 937-396-1605 Fax: 888-368-2122 |
News Archive
Inter Press Service examines the global funding shortfall for antiretroviral treatment programs for people living with HIV/AIDS, noting that the U.N. General Assembly High Level Meeting on AIDS next month in New York "will shape the direction of the global response to HIV and AIDS for the next decade and beyond."
Decompression surgery does not reduce shoulder pain any more than placebo surgery for people with shoulder impingement – when the tendon rubs and catches in the joint, according to the first placebo-controlled trial in shoulder surgery published in The Lancet.
Orthofix International N.V. today announced an internal reorganization designed to streamline operations within its three Global Business Units: Spine, Orthopedics and Sports Medicine. The Company expects to record a charge related to employee termination benefits of approximately $4.0 million ($2.4 million net of tax, or $0.13 per diluted share) in the fourth quarter of 2010 in connection with the reorganization.
The Myelin Repair Foundation today announced it has entered a Cooperative Research and Development Agreement with the National Institutes of Health to assess MRF-008, as a potential therapeutic for multiple sclerosis. This CRADA will facilitate collaboration between the MRF and National Institute of Neurological Disorders and Stroke at the NIH Clinical Center to study MRF-008, a drug identified by the MRF as a potential neuroprotective therapeutic to enhance repair in multiple sclerosis patients.
› Verified 6 days ago